Latest news

  • 10 January 2020

    Sensorion Announces its Presence in San Francisco during the 38th annual J.P. Morgan Healthcare Conference. Read

  • 23 December 2019

    Sensorion Announces Positive Data Safety Monitoring Board Review of Phase 2 trial for SENS-401 in Sudden Sensorineural Hearing Loss. Read

  • Company

    Sensorion combines world-class, scientific excellence and top-tier execution capabilities to deliver first-in-class therapeutics as a “pure player” focused on debilitating inner ear disorders. Read more

  • Pipeline

    Sensorion has two products in clinical trials, and with our efficient, in-house technology platform, we are well positioned to deliver and expand our pipeline. Read more

  • Investors

     Sensorion is focused on addressing treatment needs for 140 million of patients suffering from debilitating inner ear disorders having limited treatment options. Read more